About Aytu Biopharma Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://aytubio.com/
Frequently Asked Questions
What is the 52-week range for AYTU?
The 52-week high is $3.065 and the 52-week low is $1.8.
What is the P/E ratio for AYTU?
The P/E ratio data is currently unavailable.
What is the dividend yield for AYTU?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -52.89%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -24.76%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.65.
Analyst Recommendation Trends
Wall Street analyst consensus for AYTU over the last few months:
Latest AYTU News
Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts revised targets and ratings for KMX, ARX, JKHY, MRNA, GO, HNGE, AYTU and MSFT, with mixed upgrades, downgrades and reiterations.
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14.5 to $15.
Aytu BioPharma, Inc. Q4 2026 Earnings Call Summary
Moby summary of Aytu BioPharma, Inc.'s Q4 2026 earnings call
Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ...
Aytu BioPharma Inc (AYTU) posted $16.1 million in Q4 FY2026 revenue as EXXUA prescriptions surged 138% and the company swung to positive adjusted EBITDA of $0.5 million.
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of +77.27% and +39.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Aytu BioPharma Inc. (NASDAQ:AYTU) Shares Jump 125% on Q4 Beat and Strong EXXUA Launch
AYTU BioPharma Q4 tops estimates as EXXUA launch gains traction; shares soar 125% after hours on revenue and EPS beat, signaling strong growth.
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Fourth quarter fiscal 2026 net revenue increased 6.1 million in the prior-year quarterFourth quarter fiscal 2026 Adjusted EBITDA of $0.
Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call September 22, 2026 4:30 PM EDTCompany ParticipantsJoshua Disbrow - CEO & DirectorRyan J.
Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call
On Tuesday, Aytu BioPharma (NASDAQ:AYTU) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time
Aytu BioPharma Q4 EPS $0.00 and Sales $16.106M Beat $12.276M Estimate
Aytu BioPharma (NASDAQ:AYTU) reported quarterly sales of $16.106 million which beat the analyst consensus estimate of $12.276 million by 31.20 percent. This is a 6.42 percent increase over sales of $15.135 million the
Earnings Scheduled For September 22, 2026
Companies Reporting Before The Bell • MillerKnoll (NASDAQ:MLKN) is likely to report quarterly earnings at $0.35 per share on revenue of $943.18 million. • AutoZone (NYSE:AZO) is estimated to report quarterly earnings
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
DENVER, CO / ACCESS Newswire / September 16, 2026 / (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, September 22, 20
HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates
HeartSciences Inc. (HSCS) delivered earnings and revenue surprises of -10.26% and -97.90%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-28 | Disbrow Joshua R. | +30,000 | - | - |
| 2026-07-28 | PYSZCZYMUKA GREG | +20,000 | - | - |
| 2026-07-28 | Disbrow Jarrett | +15,000 | - | - |
| 2026-07-28 | Selhorn Ryan J | +25,000 | - | - |
| 2026-07-28 | JAIN ABHINAV | +10,000 | - | - |
| 2026-07-28 | DOCKERY CARL | +10,000 | - | - |
| 2026-07-28 | Donofrio John Jr. | +10,000 | - | - |
| 2026-07-28 | LIU VIVIAN H | +10,000 | - | - |